TY - JOUR
T1 - Practical guidelines on endoscopic treatment for Crohn's disease strictures
T2 - a consensus statement from the Global Interventional Inflammatory Bowel Disease Group
AU - Shen, Bo
AU - Kochhar, Gursimran
AU - Navaneethan, Udayakumar
AU - Farraye, Francis A.
AU - Schwartz, David A.
AU - Iacucci, Marietta
AU - Bernstein, Charles N.
AU - Dryden, Gerald
AU - Cross, Raymond
AU - Bruining, David H.
AU - Kobayashi, Taku
AU - Lukas, Martin
AU - Shergill, Amandeep
AU - Bortlik, Martin
AU - Lan, Nan
AU - Lukas, Milan
AU - Tang, Shou Jiang
AU - Kotze, Paulo Gustavo
AU - Kiran, Ravi P.
AU - Dulai, Parambir S.
AU - El-Hachem, Sandra
AU - Coelho-Prabhu, Nayantara
AU - Thakkar, Shyam
AU - Mao, Ren
AU - Chen, Guodong
AU - Zhang, Shengyu
AU - Suárez, Begoña González
AU - Lama, Yago Gonzalez
AU - Silverberg, Mark S.
AU - Sandborn, William J.
N1 - Funding Information:
DHB and WJS have received partial funding from the US National Institutes of Health. The consensus process, which included the development of the consensus statements, attendance of face-to-face meetings and voting, and electronic voting of revised consensus statements, was largely self-funded, with participants devoting their own free time and effort. In addition, the development, writing, and final approval of the manuscript were largely self-funded. Unrestricted grants (less than US$10 000 in value) were provided by Boston Scientific and OVESCO for the meeting space.
Funding Information:
DHB and WJS have received partial funding from the US National Institutes of Health. The consensus process, which included the development of the consensus statements, attendance of face-to-face meetings and voting, and electronic voting of revised consensus statements, was largely self-funded, with participants devoting their own free time and effort. In addition, the development, writing, and final approval of the manuscript were largely self-funded. Unrestricted grants (less than US$10 000 in value) were provided by Boston Scientific and OVESCO for the meeting space.
Funding Information:
BS reports educational grants and personal fees from AbbVie and Janssen, and personal fees from Takeda. GK reports grants from Boston Scientific and AbbVie. UN reports personal fees from AbbVie, Janssen, Takeda, and Pfizer. MI reports grants from Pentax, Olympus, and Fujifilm, and personal fees from Janssen. CNB reports educational grants from AbbVie Canada, Jansen Canada, Pfizer Canada, Takeda Canada, and Shire; has served on the speaker's bureau of AbbVie Canada, Takeda Canada, and Medtronic Canada; has served on the advisory board of AbbVie Canada and Jansen Canada; has been part of clinical trials for AbbVie Canada, Pfizer Canada, Shire, Boerhinger Ingelheim, Celgene, and Roche; and has been part of investigator-initiated research for AbbVie Canada. RC reports grants from AbbVie; has served as a consultant for AbbVie and Jansen; and has served on the advisory boards of AbbVie, Jansen, Pfizer, and UCB. TK reports advisory fees from Alfresa Pharma, Cavidien, Eli Lilly, Ferring Pharmaceuticals, Janssen, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kyaku, Pfizer, Takeda Pharmaceutical, and Thermo Fisher Scientific; advisory fees from AbbVie GK, Ajinomoto Pharma, Asahi Kase Medical, Astellas, Celltrion, EA Pharma, Alfresa Pharma, Kyorin Pharmceutical, Nippo Kyaku, Takeda Pharmaceutical, Machida Pharmaceutical, Mitsubishi Tanabe Pharma, ZERIA, Eisai, Gilead Science, Janssen, and JIMRO; and research grants from AbbVie GK, EA Pharma, Otsuka Holdings, ZERIA, Kyorin Pharmaceutical, Mochida Pharmaceutical, EA Pharma, Thermo Fisher Scientific, Alfresa Pharma, Nippon Kyaku, and Asahi Kasei Medical. AS reports research grants from Pentax. PGK reports personal fees from AbbVie, Janssen, Takeda, and Pfizer; YGL reports grants from AbbVie; personal fees from AbbVie, Takeda, Pfizer, and Jansen; and non-financial support from Takeda, Pfizer, Jansen, and MSD. FAF, DAS, GD, DHB, MaL, MB, NL, MiL, SZ, SJT, RPK, PSD, SHE, NCP, ST, RM, GC, BGS, MSS, and WJS declare no conflicts of interest.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/4
Y1 - 2020/4
N2 - Stricture formation is a common complication of Crohn's disease, resulting from the disease process, surgery, or drugs. Endoscopic balloon dilation has an important role in the management of strictures, with emerging techniques, such as endoscopic electroincision and stenting, showing promising results. The underlying disease process, altered bowel anatomy from disease or surgery, and concurrent use of immunosuppressive drugs can make endoscopic procedures more challenging. There is an urgent need for the standardisation of endoscopic procedures and peri-procedural management strategies. On the basis of an extensive literature review and the clinical experience of the consensus group, which consisted of representatives from the Interventional Inflammatory Bowel Disease Group, we propose detailed guidance on all aspects of the principles and techniques for endoscopic procedures in the treatment of inflammatory bowel disease-associated strictures.
AB - Stricture formation is a common complication of Crohn's disease, resulting from the disease process, surgery, or drugs. Endoscopic balloon dilation has an important role in the management of strictures, with emerging techniques, such as endoscopic electroincision and stenting, showing promising results. The underlying disease process, altered bowel anatomy from disease or surgery, and concurrent use of immunosuppressive drugs can make endoscopic procedures more challenging. There is an urgent need for the standardisation of endoscopic procedures and peri-procedural management strategies. On the basis of an extensive literature review and the clinical experience of the consensus group, which consisted of representatives from the Interventional Inflammatory Bowel Disease Group, we propose detailed guidance on all aspects of the principles and techniques for endoscopic procedures in the treatment of inflammatory bowel disease-associated strictures.
UR - http://www.scopus.com/inward/record.url?scp=85081266504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081266504&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(19)30366-8
DO - 10.1016/S2468-1253(19)30366-8
M3 - Review article
C2 - 31954438
AN - SCOPUS:85081266504
VL - 5
SP - 393
EP - 405
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
SN - 2468-1253
IS - 4
ER -